Taken together, these results indicate that CYP2C8, CYP2C9 and CYP3A5 genetic variants potentially influence in CQ/PQ malaria treatment and should be better evaluated further in larger studies to prevent ineffective treatment and adverse effects. This evidence concerns the gene CYP2C8 and malaria.